Literature DB >> 12207813

Heterogeneity in young adult onset diabetes: aetiology alters clinical characteristics.

K R Owen1, M Shepherd, A Stride, S Ellard, A T Hattersley.   

Abstract

AIMS: To describe the characteristics of hepatocyte nuclear factor (HNF) 1 alpha mutation carriers diagnosed with diabetes after 25 years and compare them with young-onset Type 2 diabetic patients (YT2D) diagnosed at the same age. SUBJECTS AND METHODS: We studied 44 (21 male, 23 female) patients with HNF-1 alpha mutations diagnosed with diabetes at ages 25-45 years and 44 YT2D subjects matched for sex and age of diagnosis.
RESULTS: Median age of onset of diabetes was 35 years in both groups. The HNF-1 alpha group demonstrated: lower body mass index (25.1 vs. 30.7 kg/m2; P < 0.001) and lower fasting triglycerides (1.37 vs. 2.96 mmol/l; P = 0.001) with similar fasting cholesterol level. They had lower glycated haemoglobin A1c (7.3 vs. 8.5%; P = 0.015) despite greater duration of diabetes (24 vs. 16 years; P = 0.02) and less frequent treatment with insulin (21% vs. 55%; P = 0.002). They were less likely to be treated for hypertension (13.3% vs. 56.3%; P = 0.009). Importantly, no difference was observed in reported parental history of diabetes between the two groups (65.9% vs. 63.6%; P = 0.92). Logistic regression showed that triglyceride levels and presence of anti-hypertensive treatment were the most important independent variables.
CONCLUSIONS: Patients with HNF-1 alpha mutations may present with diabetes as young adults between the ages of 25-45 years. In this age range a wide differential diagnosis of diabetes is observed. Conventional criteria of age of onset and family history will not differentiate HNF-1 alpha mutation carriers from YT2D subjects in this age range, but features of the metabolic syndrome, in particular fasting triglycerides and hypertension, are helpful. In patients diagnosed before 45 years without features of insulin resistance the diagnosis of HNF-1 alpha should be considered.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12207813     DOI: 10.1046/j.1464-5491.2002.00766.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  10 in total

1.  Assessment of high-sensitivity C-reactive protein levels as diagnostic discriminator of maturity-onset diabetes of the young due to HNF1A mutations.

Authors:  Katharine R Owen; Gaya Thanabalasingham; Timothy J James; Fredrik Karpe; Andrew J Farmer; Mark I McCarthy; Anna L Gloyn
Journal:  Diabetes Care       Date:  2010-08-19       Impact factor: 17.152

2.  Diabetes mellitus among young adults in Sri Lanka--role of GAD antibodies in classification and treatment: the Sri Lanka Young Diabetes study.

Authors:  P Katulanda; B Shine; G W Katulanda; A Silva; E L Asfir; R Sheriff; N Somasundaram; A E Long; P J Bingley; M I McCarthy; A Clark; D R Matthews
Journal:  Diabetologia       Date:  2008-06-05       Impact factor: 10.122

3.  Characteristics of American young adults with increased risk for type 2 diabetes: a pilot study.

Authors:  Eunseok Cha; Guillermo Umpierrez; Kevin H Kim; Morenike K Bello; Sandra B Dunbar
Journal:  Diabetes Educ       Date:  2013-05-02       Impact factor: 2.140

4.  Systematic assessment of etiology in adults with a clinical diagnosis of young-onset type 2 diabetes is a successful strategy for identifying maturity-onset diabetes of the young.

Authors:  Gaya Thanabalasingham; Aparna Pal; Mary P Selwood; Christina Dudley; Karen Fisher; Polly J Bingley; Sian Ellard; Andrew J Farmer; Mark I McCarthy; Katharine R Owen
Journal:  Diabetes Care       Date:  2012-03-19       Impact factor: 19.112

5.  Effects of hepatocyte nuclear factor-1A and -4A on pancreatic stone protein/regenerating protein and C-reactive protein gene expression: implications for maturity-onset diabetes of the young.

Authors:  Ma P Kyithar; Caroline Bonner; Siobhan Bacon; Seán M Kilbride; Jasmin Schmid; Rolf Graf; Jochen H M Prehn; Maria M Byrne
Journal:  J Transl Med       Date:  2013-06-26       Impact factor: 5.531

Review 6.  Biomarkers: Tools for Discriminating MODY from Other Diabetic Subtypes.

Authors:  Parveena Firdous; Kamran Nissar; Shariq Rashid Masoodi; Bashir Ahmad Ganai
Journal:  Indian J Endocrinol Metab       Date:  2022-08-04

7.  Circulating CD36 is reduced in HNF1A-MODY carriers.

Authors:  Siobhan Bacon; Ma P Kyithar; Jasmin Schmid; Andre Costa Pozza; Aase Handberg; Maria M Byrne
Journal:  PLoS One       Date:  2013-09-12       Impact factor: 3.240

8.  Genetic markers of inflammation may not contribute to metabolic traits in Mexican children.

Authors:  Neeti Vashi; Carolina Stryjecki; Jesus Peralta-Romero; Fernando Suarez; Jaime Gomez-Zamudio; Ana I Burguete-Garcia; Miguel Cruz; David Meyre
Journal:  PeerJ       Date:  2016-06-23       Impact factor: 2.984

Review 9.  Genetic Testing of Maturity-Onset Diabetes of the Young Current Status and Future Perspectives.

Authors:  Parveena Firdous; Kamran Nissar; Sajad Ali; Bashir Ahmad Ganai; Uzma Shabir; Toyeeba Hassan; Shariq Rashid Masoodi
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-17       Impact factor: 5.555

10.  Hidden MODY-Looking for a Needle in a Haystack.

Authors:  Jana Urbanová; Ludmila Brunerová; Jan Brož
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-02       Impact factor: 5.555

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.